Boston Scientific’s TheraSphere Trial in Japan Signals New Growth Path in Liver Cancer
Boston Scientific (BSX) announced an update on their ongoing clinical study.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Boston Scientific (BSX) is running the TheraSphere Japan Pre-Market Study to test a liver cancer treatment in patients who cannot use standard options. The official goal is to track safety and benefit of BSJ019T in Japanese patients with liver tumors, giving Boston Scientific key data for local approval and potential market expansion.
The treatment is TheraSphere Y-90 glass microsphere, a medical device delivered into the liver artery. It targets tumors from within the liver blood supply and aims to slow disease while keeping side effects manageable.
This is an interventional study with one treatment group and no random assignment to different options. There is no masking, so doctors and patients know the treatment, and the main aim is to see if it helps treat liver cancer safely.
The study was first submitted on 24 Sep 2025, marking the formal start of the regulatory process in Japan. The latest update on 18 Feb 2026 signals that the trial plan and status are current, which matters for tracking timing toward potential approval.
For investors, this update supports Boston Scientific’s push into liver cancer care in Japan and adds to its image-guided oncology franchise. Positive results could lift BSX sentiment and pressure rivals in interventional oncology, though outcomes and adoption will drive any real earnings impact.
The TheraSphere Japan Pre-Market Study remains active and updated, with more details available on the ClinicalTrials portal.
To learn more about BSX’s potential, visit the Boston Scientific drug pipeline page.
